NASDAQ:BMRA - Biomerica Stock Price, Price Target & More

$3.57 +0.02 (+0.56 %)

(As of 04/25/2018 04:00 PM ET)

Previous Close$3.55

Today's Range$3.51 - $3.70

52-Week Range$2.30 - $9.32

Volume11,946 shs

Average Volume88,163 shs

Market Capitalization$33.05 million

P/E Ratio-32.00

Dividend YieldN/A

Beta-0.63

About Biomerica (NASDAQ:BMRA)

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests. The company offers its products to hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices, as well as to distributors. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Dental equipment & supplies

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:BMRA

CUSIPN/A

Webwww.biomerica.com

Phone949-645-2111

Debt

Debt-to-Equity RatioN/A

Current Ratio5.39%

Quick Ratio2.79%

Price-To-Earnings

Trailing P/E Ratio-32.00

Forward P/E Ratio-21.00

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.79 million

Price / Sales5.33

Cash FlowN/A

Price / CashN/A

Book Value$0.46 per share

Price / Book7.76

Profitability

EPS (Most Recent Fiscal Year)($0.11)

Net Income$-900,000.00

Net Margins-19.46%

Return on Equity-27.29%

Return on Assets-23.47%

Miscellaneous

Employees39

Outstanding Shares8,650,000

How to Become a New Pot Stock Millionaire

Biomerica (NASDAQ:BMRA) Frequently Asked Questions

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

How were Biomerica's earnings last quarter?

Biomerica (NASDAQ:BMRA) posted its earnings results on Monday, April, 16th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. The company had revenue of $1.38 million for the quarter, compared to analyst estimates of $1.56 million. Biomerica had a negative net margin of 19.46% and a negative return on equity of 27.29%. View Biomerica's Earnings History.

What price target have analysts set for BMRA?

1 brokers have issued 12-month price targets for Biomerica's stock. Their predictions range from $7.50 to $7.50. On average, they anticipate Biomerica's stock price to reach $7.50 in the next twelve months. View Analyst Ratings for Biomerica.

Who are some of Biomerica's key competitors?

Some companies that are related to Biomerica include Dentsply Sirona (XRAY), Straumann (SAUHF), Sartorius (SARTF), Nobel Biocare (NBHGF), Biolase (BIOL) and Remedent (REMI).

Who are Biomerica's key executives?

Biomerica's management team includes the folowing people:

Mr. Zackary S. Irani, Chairman & CEO (Age 52)
Mr. Francis E. Capitanio, Pres (Age 74)
Ms. Janet Moore, CFO, Treasurer, Sec. & Director (Age 67)

Has Biomerica been receiving favorable news coverage?

News articles about BMRA stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Biomerica earned a news sentiment score of 0.05 on Accern's scale. They also assigned press coverage about the company an impact score of 47.60 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $3.57.

How big of a company is Biomerica?

Biomerica has a market capitalization of $33.05 million and generates $5.79 million in revenue each year. The company earns $-900,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Biomerica employs 39 workers across the globe.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.

MarketBeat Community Rating for Biomerica (BMRA)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		43 (Vote Outperform)
Underperform Votes:		38 (Vote Underperform)
Total Votes:		81

MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote "Outperform" if you believe BMRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Biomerica (NASDAQ:BMRA) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for Biomerica in the last 12 months. Their average twelve-month price target is $7.50, suggesting that the stock has a possible upside of 110.08%. The high price target for BMRA is $7.50 and the low price target for BMRA is $7.50. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	N/A
Consensus Rating Score:	3.00	3.00	3.00	N/A
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$7.50	$7.50	$7.50	N/A
Price Target Upside:	110.08% upside	87.97% upside	87.97% upside	N/A

Biomerica (NASDAQ:BMRA) Consensus Price Target History

Price Target History for Biomerica (NASDAQ:BMRA)

Biomerica (NASDAQ:BMRA) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/4/2018	B. Riley	Initiated Coverage	Buy -> Buy	$7.50	High

(Data available from 4/25/2016 forward)

Biomerica (NASDAQ:BMRA) Earnings History and Estimates Chart

Earnings by Quarter for Biomerica (NASDAQ:BMRA)

Biomerica (NASDAQ:BMRA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.19)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.03)	($0.03)	($0.03)
Q2 2018	2	($0.04)	($0.03)	($0.04)
Q3 2018	2	($0.06)	($0.05)	($0.06)
Q4 2018	2	($0.08)	($0.06)	($0.07)

Biomerica (NASDAQ BMRA) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/16/2018	Q3 2018	($0.06)	($0.0380)	$1.56 million	$1.38 million	View	N/A
1/16/2018	Q2 2018	($0.04)	($0.03)	$1.48 million	$1.61 million	View	N/A
10/16/2017	Q1 2018	($0.03)	($0.02)	$1.52 million	$1.44 million	View	N/A
8/30/2017	Q4 2017	($0.02)	($0.04)	$1.47 million	$1.45 million	View	N/A
4/14/2017	Q3 2017	($0.03)	($0.04)	$1.39 million	$1.50 million	View	N/A
1/17/2017	Q2 2017	($0.03)	($0.02)	$1.17 million	$1.43 million	View	N/A
10/17/2016	Q1 2017	($0.03)	($0.01)	$1.26 million	$1.41 million	View	N/A
8/30/2016	Q4 2016	($0.01)	($0.16)	$1.32 million	$1.33 million	View	N/A
4/14/2016	Q3 2016	($0.02)	($0.02)	$1.52 million	$1.36 million	View	N/A
1/14/2016	Q2 2016	($0.02)	($0.01)	$1.49 million	$1.17 million	View	N/A
10/15/2015	Q1 2016	($0.02)	($0.01)	$1.32 million	$1.29 million	View	N/A
9/1/2015	Q4 2015		$0.03	$1.42 million	$1.49 million	View	N/A
4/15/2015	Q3 2015	($0.01)	($0.02)	$1.50 million	$1.30 million	View	N/A
1/15/2015	Q2 2015	($0.01)	($0.03)	$1.40 million	$1.13 million	View	N/A
10/16/2014	Q1 2015	($0.03)	($0.03)	$1.24 million	$1.03 million	View	N/A
9/2/2014	Q4 2014	$0.02	$0.02	$1.43 million	$1.68 million	View	N/A
1/15/2014	Nov 2013	($0.01)	($0.03)	$1.16 million	$0.94 million	View	N/A
10/15/2013	Q1 2014		($0.02)	$1.43 million	$1.01 million	View	N/A
8/29/2013	Q4 2013		$0.01		$1.47 million	View	N/A
4/15/2013	Q3 2013	$0.03	($0.01)	$1.77 million	$1.42 million	View	N/A
1/14/2013	Q2 2013		$0.03			View	N/A
10/15/2012	Q1 2013		$0.04			View	N/A
8/29/2012	Q4 2012		$0.01			View	N/A
4/17/2012	Q3 2012		$0.03			View	N/A
1/17/2012	Q2 2012		$0.03			View	N/A
10/18/2011	Q1 2012		$0.02			View	N/A
8/30/2011	Q4 2011		$0.01			View	N/A
4/15/2011	Q3 2011		$0.01			View	N/A
4/15/2010	Q3 2010		$0.02			View	N/A
1/19/2010	Q2 2010		($0.05)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Biomerica (NASDAQ:BMRA) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Biomerica (NASDAQ BMRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 26.30%
Institutional Ownership Percentage: 1.27%

Insider Trading History for Biomerica (NASDAQ:BMRA)

Biomerica (NASDAQ BMRA) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/9/2018	Zackary S Irani	CEO	Buy	500	$3.83	$1,915.00	860,539
2/2/2018	Zackary S Irani	CEO	Buy	1,000	$3.96	$3,960.00	860,039
1/25/2018	Francis Cano	Director	Buy	11,800	$4.18	$49,324.00	128,036
1/25/2018	Zackary S Irani	CEO	Buy	2,039	$4.03	$8,217.17	857,000
1/23/2018	Zackary S Irani	CEO	Buy	500	$3.85	$1,925.00	857,000
2/27/2017	Francis E Capitanio	President	Sell	15,000	$2.46	$36,900.00	102,000
1/4/2017	Janet Moore	CFO	Sell	4,500	$2.20	$9,900.00	145,220
12/22/2016	Janet Moore	CFO	Sell	9,780	$2.18	$21,320.40	142,000
12/12/2016	Francis E Capitanio	President	Sell	9,351	$2.77	$25,902.27	96,351
12/8/2016	Francis E Capitanio	President	Sell	10,649	$2.89	$30,775.61	90,649
11/14/2016	Zackary S Irani	CEO	Buy	400	$1.94	$776.00	781,200
11/8/2016	Zackary S Irani	CEO	Buy	500	$1.74	$870.00	781,000
11/4/2016	Zackary S Irani	CEO	Buy	1,000	$1.95	$1,950.00	780,600
10/20/2016	Francis E Capitanio	President	Sell	10,000	$2.68	$26,800.00	82,000
10/3/2016	Jane Emerson	Director	Buy	1,000	$2.80	$2,800.00	21,000
9/7/2016	Zackary S Irani	CEO	Buy	199	$2.65	$527.35	779,600
8/12/2016	Janet Moore	CFO	Buy	2,200	$2.98	$6,556.00	121,000
8/12/2016	Zackary S Irani	Insider	Buy	3,166	$2.98	$9,434.68	776,435
8/11/2016	Zackary S Irani	CEO	Buy	3,700	$2.88	$10,656.00	773,035
8/10/2016	Zackary S Irani	CEO	Buy	1,000	$2.72	$2,720.00	771,935
8/9/2016	Allen Barbieri	Director	Buy	3,000	$2.54	$7,620.00	99,889
8/5/2016	Francis Cano	Director	Buy	16,300	$2.37	$38,631.00	82,100
8/3/2016	Mark A Sirgo	Director	Buy	4,000	$2.05	$8,200.00	12,000
8/3/2016	Zackary S Irani	CEO	Buy	2,609	$2.10	$5,478.90	769,926
8/2/2016	Mark A Sirgo	Director	Buy	8,000	$1.97	$15,760.00	2,000
8/1/2016	Zackary S Irani	CEO	Buy	5,400	$1.88	$10,152.00	765,926
5/16/2016	Francis E Capitanio	President	Sell	20,000	$1.50	$30,000.00	87,000
11/13/2015	Zackary S Irani	CEO	Buy	5,000	$0.83	$4,150.00	711,526
6/8/2015	Zackary S Irani	CEO	Buy	3,000	$1.08	$3,240.00
5/22/2015	Zackary S Irani	CEO	Buy	2,000	$0.85	$1,700.00
5/11/2015	Zackary S Irani	CEO	Buy	18,000	$0.91	$16,380.00
9/6/2012	Zackary S Irani	CEO	Buy	7,000	$0.70	$4,900.00

(Data available from 1/1/2013 forward)

Biomerica (NASDAQ BMRA) News Headlines

Source:

Date	Headline
	Biomerica adds Harry Leider, MD, MBA to Strategic Advisory Board finance.yahoo.com - April 19 at 10:01 AM
	BMRA: Q3 2018 Results: Asia Remains Strong While U.S., Europe Slip. Encouraged By Robustness of InFoods Study Design finance.yahoo.com - April 19 at 10:01 AM
	Biomerica (BMRA) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS www.americanbankingnews.com - April 18 at 9:54 AM
	Does Biomerica Inc’s (NASDAQ:BMRA) Past Performance Indicate A Stronger Future? finance.yahoo.com - April 17 at 4:22 PM
	Biomerica Announces Third Quarter Financial Results finance.yahoo.com - April 17 at 10:20 AM
	Biomerica (BMRA) Downgraded to "Sell" at ValuEngine www.americanbankingnews.com - April 10 at 7:51 PM
	Biomerica (BMRA) Now Covered by Analysts at B. Riley www.americanbankingnews.com - March 30 at 5:08 PM
	Mexico’s COFEPRIS (Mexico’s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer finance.yahoo.com - March 8 at 10:28 AM
	Biomerica Inc (NASDAQ:BMRA): Is Breakeven Near? finance.yahoo.com - March 2 at 9:51 AM
	FY2018 Earnings Estimate for Biomerica, Inc. Issued By B. Riley (BMRA) www.americanbankingnews.com - February 9 at 1:43 PM
	Francis Cano Acquires 11,800 Shares of Biomerica, Inc. (BMRA) Stock www.americanbankingnews.com - January 25 at 9:44 PM
	Zacks Investment Research Weighs in on Biomerica, Inc.'s Q3 2018 Earnings (BMRA) www.americanbankingnews.com - January 25 at 11:28 AM
	BMRA: Moving Price Target to $7/Share With Inclusion of InFoods finance.yahoo.com - January 23 at 4:26 PM
	Biomerica, Inc. :BMRA-US: Earnings Analysis: Q2, 2018 By the Numbers : January 19, 2018 finance.yahoo.com - January 19 at 6:21 PM
	Biomerica (BMRA) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS www.americanbankingnews.com - January 17 at 1:34 PM
	Biomerica Announces Second Quarter Financial Results; Sales Up 12.7% for the Quarter finance.yahoo.com - January 16 at 5:37 PM
	Biomerica, Inc. (BMRA) Announces China FDA Approval of Colorectal Screening Test to help Identify Early Warning Signs of Colorectal Cancer www.streetinsider.com - January 11 at 9:23 AM
	BRIEF-China FDA Approves Biomerica Colorectal Screening Test To Help Identify The Early Warning Signs Of Colorectal Cancer www.reuters.com - January 10 at 5:39 PM
	China Food and Drug Administration (CFDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer finance.yahoo.com - January 10 at 9:11 AM
	Biomerica Inc (NASDAQ:BMRA): Poised For Long-Term Success? finance.yahoo.com - January 9 at 9:10 AM
	Biomerica Signs Agreements with Beth Israel Deaconess & University of Michigan to Initiate Clinical Study for First of a Kind, Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy (DGT) finance.yahoo.com - January 8 at 5:50 PM
	Q2 2018 Earnings Estimate for Biomerica, Inc. (BMRA) Issued By B. Riley www.americanbankingnews.com - January 8 at 6:38 AM
	Is Biomerica Inc (NASDAQ:BMRA) Thriving Or Barely Surviving In The Healthcare Sector? finance.yahoo.com - January 2 at 9:06 AM
	Does Biomerica Inc’s (NASDAQ:BMRA) Earnings Growth Make It An Outperformer? finance.yahoo.com - December 25 at 7:19 PM
	What You Must Know About Biomerica Inc’s (BMRA) Financial Health finance.yahoo.com - December 7 at 6:13 PM
	BRIEF-Biomerica Enters Into At Market Issuance Sales Agreement With B. Riley FBR www.reuters.com - December 4 at 9:01 AM
	Biomerica (BMRA) Cut to Sell at ValuEngine www.americanbankingnews.com - December 3 at 9:26 PM
	Biomerica Announces Enrollment of First Patient for H. Pylori Clinical Studies at the University of Southern California finance.yahoo.com - November 20 at 5:50 PM

Biomerica (NASDAQ:BMRA) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Biomerica (NASDAQ:BMRA) Income Statement, Balance Sheet and Cash Flow Statement

Biomerica (NASDAQ BMRA) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff